UAB30, a Novel RXR Agonist, Decreases Tumorigenesis and Leptomeningeal Disease in Group 3 Medulloblastoma Patient-Derived Xenografts

BACKGROUND: Group 3 tumors account for approximately 25–30% of medulloblastomas and have the worst prognosis. UAB30 is a novel synthetic rexinoid shown to have limited toxicities in humans and significant efficacy in the pediatric neuroectodermal tumor, neuroblastoma. We hypothesized that treatment...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Neurooncol
Main Authors: Garner, Evan F., Stafman, Laura L., Williams, Adele P., Aye, Jamie M., Goolsby, Caroline, Atigadda, Venkatram R., Moore, Blake P., Nan, Li, Stewart, Jerry E., Hjelmeland, Anita B., Friedman, Gregory K., Beierle, Elizabeth A.
Format: Artigo
Jezik:Inglês
Izdano: 2018
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6239946/
https://ncbi.nlm.nih.gov/pubmed/30132166
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-018-2950-1
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki